Psychedelics in Mental Health: Progress and Challenges

This chapter explores the emerging role of psychedelics like ketamine, MDMA, and psilocybin in mental health therapy, addressing the progress of scientific research and regulatory hurdles. It highlights ongoing clinical trials, the potential for these substances to become mainstream therapeutic options, and the existing underground practices among therapists. The conversation also touches on cultural perceptions, safety concerns, and the intricate balance between medical benefits and the risks of commercialization.